Advertiment
Symphogen announced today that the company will present preliminary Phase 1 data evaluating the company’s lead cancer compound, Sym004, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago. At the General Poster Session on June 6 from 8 AM to 12 PM, preliminary results from the ongoing Phase 1 open-label, multi-center dose escalation trial evaluating the safety and tolerability of multiple doses of Sym004 will be provided. The poster is entitled “Phase I Trial Of The First-In-Class EGFR mAb Mixture, Sym004, In Patients With Refractory Advanced Solid Tumors” by Dr. Rodrigo Dienstmann of the Vall d’Hebron University Hospital, Barcelona, Spain.
About Sym004
Sym004 is a novel anti-EGFR monoclonal antibody (mAb) mixture, comprised of two mAbs that targets two distinct and non-overlapping epitopes in domain III of EGFR. The two mAbs rapidly eliminate EGFR and lead to cancer cell death (Pedersen et al (2010) Cancer Research).
Source:
Symphogen
Related Search
symphogen 2012,
Leave a Reply
Suggested Posts
3-D RNA Modeling Opens Scientific Doors Symphoge a ou ced today that the compa y will prese t prelimi ary Phase 1 data evaluati g the compa y’s lead ca cer compou d, Sym004, at the 2011 A ual Meeti g of the America Society of Cli ical O cology i Chicago. At the Ge eral Poster Sessio o Ju e 6 from 8 AM to 12 PM, prelimi ary results from the o goi g Phase 1 ope -label, [...]. Posted June 4th, 2011 | 7:46 pm
Potential New Treatment For Kidney Cancer By Specific Inhibition Of Autophagy Symphoge a ou ced today that the compa y will prese t prelimi ary Phase 1 data evaluati g the compa y’s lead ca cer compou d, Sym004, at the 2011 A ual Meeti g of the America Society of Cli ical O cology i Chicago. At the Ge eral Poster Sessio o Ju e 6 from 8 AM to 12 PM, prelimi ary results from the o goi g Phase 1 ope -label, [...]. Posted June 4th, 2011 | 7:46 pm
Altering Tumor Microenvironment Shown To Boost Response To Cancer Drugs During Live Imaging Symphoge a ou ced today that the compa y will prese t prelimi ary Phase 1 data evaluati g the compa y’s lead ca cer compou d, Sym004, at the 2011 A ual Meeti g of the America Society of Cli ical O cology i Chicago. At the Ge eral Poster Sessio o Ju e 6 from 8 AM to 12 PM, prelimi ary results from the o goi g Phase 1 ope -label, [...]. Posted June 4th, 2011 | 7:46 pm
Cancer Gene MCL1 Targeted Symphoge a ou ced today that the compa y will prese t prelimi ary Phase 1 data evaluati g the compa y’s lead ca cer compou d, Sym004, at the 2011 A ual Meeti g of the America Society of Cli ical O cology i Chicago. At the Ge eral Poster Sessio o Ju e 6 from 8 AM to 12 PM, prelimi ary results from the o goi g Phase 1 ope -label, [...]. Posted June 4th, 2011 | 7:46 pm
Study Finds Cancer Related Pain Often Under-Treated Symphoge a ou ced today that the compa y will prese t prelimi ary Phase 1 data evaluati g the compa y’s lead ca cer compou d, Sym004, at the 2011 A ual Meeti g of the America Society of Cli ical O cology i Chicago. At the Ge eral Poster Sessio o Ju e 6 from 8 AM to 12 PM, prelimi ary results from the o goi g Phase 1 ope -label, [...]. Posted June 4th, 2011 | 7:46 pm